Skip to main content
. Author manuscript; available in PMC: 2020 Sep 17.
Published in final edited form as: Aliment Pharmacol Ther. 2018 Aug 22;48(7):696–703. doi: 10.1111/apt.14937

FIGURE 2.

FIGURE 2

A, Pooled measure of effects for NASH and HCC in all patients (either with or without cirrhosis). There was a trend towards significance with increased risk of HCC when comparing NASH patients to all other aetiologies of liver disease, however, this was not statistically significant. B, Pooled measure of effects of NASH and HCC in patients without cirrhosis. The overall pooled estimate from the seven studies indicates that patients with NASH have a 261% increased risk of HCC when compared to all other aetiologies of liver disease